[
  {
    "objectID": "blog/sergeant2018/index.html",
    "href": "blog/sergeant2018/index.html",
    "title": "Sergeant et al., 2018",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjective\n\nTo identify baseline predictors of non-response to MTX and combine these into a prediction algorithm.\n\nRelated articles\n\nFor more articles on prediction of MTX treatment response, see Duong et al., 2022, Myasoedova et al., 2021, Castrejón et al., 2016.\n\nLink\n\nDOI: https://doi.org/10.1186/s13075-018-1645-5"
  },
  {
    "objectID": "blog/sergeant2018/index.html#background",
    "href": "blog/sergeant2018/index.html#background",
    "title": "Sergeant et al., 2018",
    "section": "Background",
    "text": "Background\n\nMTX is the DMARD of choice in anti-rheumatic treatment\nResponse to MTX varies between patients"
  },
  {
    "objectID": "blog/sergeant2018/index.html#methods",
    "href": "blog/sergeant2018/index.html#methods",
    "title": "Sergeant et al., 2018",
    "section": "Methods",
    "text": "Methods\n\nParticipants from the UK multi-center prospective observational study RAMS (RA medication study)\nMTX-naïve patients\nNon-response was defined as “no response” after the EULAR response criteria (see also Smolen et al., 2020), discontinuation of MTX due to inefficacy or starting biologic therapy\nTested association of baseline demographic, clinical and psychosocial predictors with non-response using logistic regression\nAUC and calibration plots to assess predictive performance"
  },
  {
    "objectID": "blog/sergeant2018/index.html#results",
    "href": "blog/sergeant2018/index.html#results",
    "title": "Sergeant et al., 2018",
    "section": "Results",
    "text": "Results\n\n43% of patients were classified as non-responders\nindependent multivariable predictors of MTX non-response were RF negativity, higher HAQ, higher TJC, lower DAS28 and higher Hospital Anxiety and Depression Scale anxiety score\nOptimism-corrected (huh?) AUC was 0.74"
  },
  {
    "objectID": "blog/sergeant2018/index.html#conclusions",
    "href": "blog/sergeant2018/index.html#conclusions",
    "title": "Sergeant et al., 2018",
    "section": "Conclusions",
    "text": "Conclusions\n\nFirst MTX non-response model to be developed in a large cohort where MTX starters where analysed with demographic, clinical and psychosocial predictors\nAnxiety is a predictor of non-response and could be addressed at treatment commencement"
  },
  {
    "objectID": "blog/duong2022/index.html",
    "href": "blog/duong2022/index.html",
    "title": "Duong et al., 2022",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjectives\n\nTo identify clinical predictors of response to MTX in patients with RA using ML methods.\n\nRelated articles\n\nPrediction of treatment response (Capelusnik & Aletaha, 2021, Sergeant et al., 2018, Castrejón et al., 2016).\n\nLink\n\nDOI: https://doi.org/10.1186/s13075-022-02851-5"
  },
  {
    "objectID": "blog/duong2022/index.html#background",
    "href": "blog/duong2022/index.html#background",
    "title": "Duong et al., 2022",
    "section": "Background",
    "text": "Background\n\nMTX is the popular first-line DMARD treatment in RA\nThere are no clinically useful tools to predict response to MTX treatment in patients with RA"
  },
  {
    "objectID": "blog/duong2022/index.html#methods",
    "href": "blog/duong2022/index.html#methods",
    "title": "Duong et al., 2022",
    "section": "Methods",
    "text": "Methods\n\nDMARD-naïve patients with RA from RCTs were accessed through a database\nRequired DAS28-ESR at baseline and 12 and 24 weeks\nLatent class modelling of MTX response\nLasso and random forests were used to identify predictors of response\nModel performance was assessed using AUC"
  },
  {
    "objectID": "blog/duong2022/index.html#results",
    "href": "blog/duong2022/index.html#results",
    "title": "Duong et al., 2022",
    "section": "Results",
    "text": "Results\n\n775 patients from 4 RCTs were included\nTwo classes of patients were identified based on DAS28-ESR change over 24 weeks: good vs poor responders\nTop predictors were baseline DAS28, ACPA, HAQ – highest likelihood of response in DAS28 &lt; 7.4, ACPA positive, HAQ &lt; 2\nIsn’t this a bit of a no brainer? If you’re doing better at the start, you’re more likely to achieve a certain low threshold after a short amount of time? See also Capelusnik & Aletaha, 2021."
  },
  {
    "objectID": "blog/duong2022/index.html#conclusions",
    "href": "blog/duong2022/index.html#conclusions",
    "title": "Duong et al., 2022",
    "section": "Conclusions",
    "text": "Conclusions\n\nDeveloped and externally validated a prediction model for response to MTX within 24 weeks in DMARD-naïve patients with RA\nOne of the first studies to use ML methods to identify latent trajectories of DAS28-ESR over 24 weeks\n\n\n\n\n\n\n\nHeterogeneous responses to MTX unaccounted for in treatment guidelines\n\n\n\nThe vast heterogeneity in response to MTX among individual patients with RA is insufficiently addressed in the current treatment guidelines, and systematic patient-tailored tools to personalize early RA management are lacking (for more information on treatment guidelines, see Smolen et al., 2020, Fraenkel et al., 2021).\n\n\n\nLower baseline disease activity and better functional status are predictive of good responders to MTX is in line with previous studies ([[Capelusnik & Aletaha, 2021]], [[Sergeant et al., 2018]], [[Castrejón et al., 2016]])\nAuthors claim that people below certain cutoffs (see [[#Results]]) have an 80% probability of responding to MTX treatment, but it is unclear to me how much uncertainty there is on an individual level – after all, this prediction should only matter on an individual level\n\n\n\n\n\n\n\nMore discussion\n\n\n\nThe authors go into further detail about - Relevance of different time windows - Relevance of ACPA positivity - Relevance of individual DAS28 components for prediction and point to another study from the Netherlands where this was similar (see here, yet to be summarised) - Sociodemographic characteristics - External validation of results - Limitations and strengths of their study"
  },
  {
    "objectID": "blog/index.html",
    "href": "blog/index.html",
    "title": "Recent articles",
    "section": "",
    "text": "Order By\n       Default\n         \n          Title\n        \n         \n          Date - Oldest\n        \n         \n          Date - Newest\n        \n         \n          Author\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n\nCastrejón et al., 2018\n\n\nPrediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) \n\n\n\nRheumatoid arthritis\n\n\nPrediction\n\n\nComposites\n\n\n\n\n\n\nMay 31, 2024\n\n\nSimon Steiger\n\n\n\n\n\n\n\nSergeant et al., 2018\n\n\nPrediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) \n\n\n\nRheumatoid arthritis\n\n\nTreatment response\n\n\nPrediction\n\n\nComposites\n\n\n\n\n\n\nMay 30, 2024\n\n\nSimon Steiger\n\n\n\n\n\n\n\nPadyukov, L., 2022\n\n\nGenetics of rheumatoid arthritis \n\n\n\nAlleles\n\n\nArthritis\n\n\nRheumatoid/etiology/genetics\n\n\nAutoantibodies\n\n\nGenetic Predisposition to Disease\n\n\nHLA-DRB1 Chains/genetics\n\n\nHumans\n\n\nProteomics\n\n\nAutoantibody\n\n\nAutoimmunity\n\n\nGenetic polymorphism\n\n\nHla\n\n\nInflammation\n\n\nRheumatoid arthritis\n\n\n\n\n\n\nMay 29, 2024\n\n\nYounes Laalou\n\n\n\n\n\n\n\nSmolen et al., 2020\n\n\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update \n\n\n\nRheumatoid arthritis\n\n\nTreatment\n\n\nGuidelines\n\n\n\n\n\n\nMay 27, 2024\n\n\nSimon Steiger\n\n\n\n\n\n\n\nMyasoedova et al., 2021\n\n\nToward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics-Driven Machine Learning Approach \n\n\n\nRheumatoid arthritis\n\n\nTreatment response\n\n\nPrediction\n\n\nComposites\n\n\nGenetics\n\n\n\n\n\n\nMay 25, 2024\n\n\nSimon Steiger\n\n\n\n\n\n\n\nDuong et al., 2022\n\n\nClinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data \n\n\n\nRheumatoid arthritis\n\n\nTreatment response\n\n\nPrediction\n\n\nComposites\n\n\n\n\n\n\nMay 23, 2024\n\n\nSimon Steiger\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "blog/myasoedova2021/index.html",
    "href": "blog/myasoedova2021/index.html",
    "title": "Myasoedova et al., 2021",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjective\n\nTo test the ability of ML approaches with clinical and genomic biomarkers to predict MTX treatment response in patients with early RA.\n\nRelated articles\n\nFor more articles on prediction of MTX treatment response, see Duong et al., 2022, Sergeant et al., 2018, Castrejón et al., 2016.\n\nLink\n\nDOI: https://doi.org/10.1002/acr.24834"
  },
  {
    "objectID": "blog/myasoedova2021/index.html#background",
    "href": "blog/myasoedova2021/index.html#background",
    "title": "Myasoedova et al., 2021",
    "section": "Background",
    "text": "Background\n\nMTX may be the only drug necessary to control RA for some, but in 30-40% there is no response\n50% of patients discontinue MTX within 3-5 years (Aletaha & Smolen, 2002)\nComposite disease activity measures reflect a clinically meaningful target of reaching low disease activity (see Van Gestel et al., 1996, Van Gestel et al., 1998, and Fransen & van Riel, 2005)"
  },
  {
    "objectID": "blog/myasoedova2021/index.html#methods",
    "href": "blog/myasoedova2021/index.html#methods",
    "title": "Myasoedova et al., 2021",
    "section": "Methods",
    "text": "Methods\n\nDemographic, clinical and genomic data of 643 european-ancestry patients with early RA\nResponse to MTX was defined as good or moderate by the EULAR response criteria at the 3-month follow-up\nRandom forests were trained and prediction performance was evaluated with AUC"
  },
  {
    "objectID": "blog/myasoedova2021/index.html#results",
    "href": "blog/myasoedova2021/index.html#results",
    "title": "Myasoedova et al., 2021",
    "section": "Results",
    "text": "Results\n\nIn-sample AUC 0.84, out-of-sample prediction accuracy 76% (with p values for both, lol?)\nIntergenic SNPs had variable importance above 60 (whatever that means), and among with baseline DAS28 were the top predictors of MTX response"
  },
  {
    "objectID": "blog/myasoedova2021/index.html#conclusion",
    "href": "blog/myasoedova2021/index.html#conclusion",
    "title": "Myasoedova et al., 2021",
    "section": "Conclusion",
    "text": "Conclusion\n\nPharmacogenomic biomarkers combined with baseline DAS28 can be useful in predicting response to MTX in patients with early RA\nML is promising in this area, potentially able to predict timely escalation of treatment strategies in early RA"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "KEPipedia",
    "section": "",
    "text": "This is a Quarto website.\nTo learn more about Quarto websites visit https://quarto.org/docs/websites."
  },
  {
    "objectID": "blog/smolen2020/index.html",
    "href": "blog/smolen2020/index.html",
    "title": "Smolen et al., 2020",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjectives\n\nTo provide an update of the European League Against Rheumatism (EULAR) RA management recommendations to account for the most recent developments in the field.\n\nRelated articles\n\nTreatment recommendations by the ACR (Fraenkel et al., 2021).\n\nLink\n\nDOI: https://doi.org/10.1136/annrheumdis-2019-216655"
  },
  {
    "objectID": "blog/smolen2020/index.html#methods",
    "href": "blog/smolen2020/index.html#methods",
    "title": "Smolen et al., 2020",
    "section": "Methods",
    "text": "Methods\n\nSummarise new supporting or contradicting evidence for therapies\nLiterature search and predefined voting process on current levels of evidence"
  },
  {
    "objectID": "blog/smolen2020/index.html#results",
    "href": "blog/smolen2020/index.html#results",
    "title": "Smolen et al., 2020",
    "section": "Results",
    "text": "Results\n\nTask force agreed on five overarching principles and 12 recommendations concerning use of csDMARDs (MTX, leflunomide, sulfasalizine), glucocorticoids (GCs), bDMARDs (TNFis), and tsDMARDs (JAKis)\nGuidance on monotherapy, combination therapy, treatment strategy (treat-to-target) and tapering on sustained clinical remission is provided\n\nBegin with MTX plus GCs and upon insufficient response within 3 to 6 months, stratify by risk factors\nIn the presence of poor prognostic factors (autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAKi should be added to the csDMARD\nAdd a bDMARD (another or same class) or tsDMARD is recommended\n\n\n\n\n\n\n\n\nDefining MTX failure\n\n\n\nAccording to this definition, MTX treatment has been unsuccessful once a patient adds any bDMARD or JAKi. Classifying initial treatment success for MTX in SRQ should therefore look for the addition of other drugs and not the stopping date of MTX.\n\n\n\nOn sustained remission, DMARDs may be tapered but not stopped\nLevels of agreement among experts were high mostly"
  },
  {
    "objectID": "blog/smolen2020/index.html#conclusion",
    "href": "blog/smolen2020/index.html#conclusion",
    "title": "Smolen et al., 2020",
    "section": "Conclusion",
    "text": "Conclusion\nWIP"
  },
  {
    "objectID": "blog/castrejon2016/index.html",
    "href": "blog/castrejon2016/index.html",
    "title": "Castrejón et al., 2018",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjective\n\nTo identify baseline variables that predict remission according to different criteria in RA\n\nRelated articles\n\nFor more articles on prediction of MTX treatment response, see Duong et al., 2022, Myasoedova et al., 2021, Sergeant et al., 2018.\n\nLink\n\nDOI: https://doi.org/10.3899/jrheum.141586"
  },
  {
    "objectID": "blog/castrejon2016/index.html#background",
    "href": "blog/castrejon2016/index.html#background",
    "title": "Castrejón et al., 2018",
    "section": "Background",
    "text": "Background\nTODO"
  },
  {
    "objectID": "blog/castrejon2016/index.html#methods",
    "href": "blog/castrejon2016/index.html#methods",
    "title": "Castrejón et al., 2018",
    "section": "Methods",
    "text": "Methods\n\nAnalysed individual variables and indices at baseline\nPredicted remission at either 6 or 12 months according to Boolean remission, SDAI, CDAI and DAS28"
  },
  {
    "objectID": "blog/castrejon2016/index.html#results",
    "href": "blog/castrejon2016/index.html#results",
    "title": "Castrejón et al., 2018",
    "section": "Results",
    "text": "Results\n\nRemission was predicted “significantly” (?) in 27 to 51 percent of patients\nRelevant predictors were younger age, low scores (no brainer? see also Capelusnik & Aletaha, 2021) on composites and their components, HAQ, pain, etc\nRemission was not predicted by the absence of “poor prognosis RA” (meaning “difficult to treat RA”?) or radiographic erosions\nIn multivariate regressions that included only three variables (sounds like some model selection?) low HAQ predicted remission according to all criteria as effectively as SJC, ESR, or CRP"
  },
  {
    "objectID": "blog/castrejon2016/index.html#conclusions",
    "href": "blog/castrejon2016/index.html#conclusions",
    "title": "Castrejón et al., 2018",
    "section": "Conclusions",
    "text": "Conclusions\n\nYounger age and (low scores on) six core data set clinical measures predicted remission\nAbsence of traditional “poor prognosis RA” indicators, RA, ACPA, or radiographic erosions did not predict remission"
  },
  {
    "objectID": "blog/leonidpadyukov2022/index.html",
    "href": "blog/leonidpadyukov2022/index.html",
    "title": "Padyukov, L., 2022",
    "section": "",
    "text": "At a glance\n\n\n\n\nObjectives\n\n\n\n\nRelated articles :\n\nLink\n\nDOI: [https://doi.org/10.1007/s00281-022-00912-0]"
  }
]